|10-666-B||A Phase Ib, Open label, Dose-Escalation Study evaluating the Safety, Tolerability and Pharmacokinetics of RO5185426 in Combination with GDC-0973 when Administered in Patients with BRAFV600E-Positive Metastatic Melanoma who have Progressed after treatment with RO5185426
|11-0375||ECOG E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-risk Melanoma
To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.